Cell Surface Marker Expression in Autoimmune Diseases (CASCADE)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.
Read our disclaimer for details.
This study is designed to explore the expression of cell-surface markers in the following seven disease areas: (a) systemic lupus erythematosus, (b) Sjogren's syndrome, (c) multiple sclerosis, (d) systemic sclerosis, (e) Crohn's disease, (f) ulcerative colitis and (g) inflammatorymyositis.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
19 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Adults with systemic lupus erythematosus, Sjogren's syndrome, systemic sclerosis, multiple sclerosis, Crohn's disease, ulcerative colitis, or inflammatory myositis.
Male or female participants 19 years of age or older.
Participant or legal surrogate able and willing to provide written, informed consent.
Participant is, or has been undergoing care for one of the specified diseases in a participating centre with a confirmed clinical diagnosis of the specified disease.
Participant has or will provide the relevant peripheral blood (required) and normal practice tissue specimens (if available).
Participant has one of the following target auto-immune or inflammatory diseases diagnosed according to local clinical practice guidelines:
Systemic lupus erythematosus
Participants receiving investigational therapy within 30 days or 5 half-lives, whichever is longer, prior to enrolment.
Participants suffering from any additional disease that may interfere with the biomarker signals as per the investigator's discretion.